On June 12 this year, the authoritative medical and health platform Minenet released the Blue Book "Analysis of Drug Use in Physical Pharmacies in the Three Terminals and Six Markets", which pointed out that the total drug sales in China's physical pharmacy market in 2023 will reach 487 billion yuan, accounting for 25.8% of the national drug market, and a steady growth of 3.6% compared with 2022.
In a further breakdown of the data, we see that the relevant antiviral therapeutics and newly launched innovative drugs performed well, and these drugs achieved excellent market performance in 2023, which shows that the timeliness of physical stores still plays an advantage.
Baiyun Mountain Jinge sold 1.5 billion yuan, ranking TOP7 in the sales list of urban physical pharmacies
According to the report, among the sales amount of various categories in the chemical drug market, systemic anti-infective drugs, digestive system and metabolic drugs, cardiovascular and cerebrovascular system drugs, anti-tumor and immunomodulators are among the top four. Focusing on specific brands, a total of 8 brands have successfully sprinted to the ranks of 1.5 billion sales.
(In the TOP10, the sales of "sildenafil citrate tablets" exceeded 3 billion yuan, achieving the first category of drugs for national welfare)
In the ranking, Baiyunshan Jinge (sildenafil citrate tablets) is also among them as a genitourinary system and sex hormone drug, with sales of 1.5 billion yuan, an increase of 14.9% year-on-year. Since its launch in 2014, the product has been warmly welcomed by consumers. Checking the annual report of Guangzhou Pharmaceutical Baiyunshan, it was found that Baiyunshan Jinge's performance has repeatedly reached new highs since its listing. In particular, the 2023 annual report shows that the sales volume of the drug reached 101 million tablets, recording an operating income of nearly 1.3 billion yuan, a year-on-year increase of 22.58%.
(Baiyunshan Jinge's operating income in 2023 will reach 1.289 billion yuan.) Screenshot source: Baiyun Mountain 2023 annual report)
It is also worth mentioning that last year, Baiyunshan Jinge entered the TOP10 chemical drug market in China's urban physical pharmacies with sales of 1.3 billion yuan, and it is expected that it will be ranked TOP7 again this year.
In fact, the research and development process of "sildenafil" is quite legendary. The development of sildenafil began in the late 80s of the 20th century, when scientists were working on a compound called "UK-92480" in the hope that it would treat cardiovascular diseases. However, in clinical trials, the compound did not work as well as expected in the treatment of cardiovascular disease, but scientists unexpectedly found that male patients who participated in the trial were less willing to return the remaining medicines. Upon further inquiry, it was learned that although the compound had limited therapeutic effect on cardiovascular disease, it significantly improved erectile function in men with erectile dysfunction.
Subsequently, scientists conducted further research and development of this compound and named it "sildenafil". After years of clinical trials and approvals, "sildenafil" was finally approved by the FDA in 1998, becoming the world's first oral drug for the treatment of male erectile dysfunction.
The launch of "sildenafil" has attracted widespread attention, and it has brought new treatment options for male patients with erectile dysfunction. When the patent protection expired in 2014, Chinese pharmaceutical companies began producing and selling similar drugs. Among them, the Jinge product launched by Guangyao Baiyunshan was particularly eye-catching, and was praised by the industry as the first "domestic Viagra" at that time, and it attracted extensive attention and expectations from the media and consumers when it was launched.
In recent years, Baiyunshan Jinge has become the star product of Guangzhou Pharmaceutical Baiyunshan, and the success of this drug not only demonstrates the R&D strength and market insight of Guangzhou Pharmaceutical Baiyunshan, but also brings new hope to the field of men's health.
The common responsibility of society: pay attention to men's health and improve the sexual well-being index
With the acceleration of the pace of modern life, the incidence of men's health diseases is gradually increasing due to multiple factors such as increasing life pressure, bad living habits and environmental pollution, and this problem is becoming more and more prominent.
Erectile dysfunction (ED), in particular, not only affects the quality of a man's sexual life, but is also an important indicator of his overall physical and mental health. According to an authoritative survey by the World Health Organization in 2013, andrological diseases have become a major threat to men's health worldwide. Specific to the mainland, the situation is equally grim: according to data from the China Health Education Center, erectile dysfunction (ED) is one of the diseases with a high incidence of male reproductive system, and the overall prevalence of male erectile dysfunction in Chinese mainland has reached a staggering 26.1%, and the prevalence rate of people over 40 years old has climbed to 40.2%. These figures are undoubtedly a wake-up call to our society that we must pay enough attention to men's health.
However, despite the increasing prevalence of health disorders in men, studies have found that only 6% of patients with ED[1] choose to seek medical attention. Nearly half of patients with ED do not seek treatment in a formal hospital, preferring to consult online or search for solutions on their own [2]. This phenomenon reflects the social neglect and misunderstanding of men's sexual health issues, as well as the embarrassment and avoidance that patients themselves may have.
According to the Blue Book of China's Six Major End-use Drug Markets, ED patients are gradually getting younger, and the number of cases is increasing year by year. It is worth noting that the proportion of self-medication is as high as more than 80% when dealing with personal ED problems, and the use of anti-ED drugs to assist sex has become a trend, which also promotes the continuous growth of the demand for drugs such as Jinge.
As a leading "sildenafil" brand in China, Baiyunshan Jinge has been steadily listed for ten years. With its remarkable efficacy and wide market recognition, it has become one of the preferred treatment modalities for ED patients. We hope that with the progress of society and the openness of ideas, more and more men will be able to face their health problems calmly and actively seek scientific and effective treatments. At the same time, we also call on the whole society to work together to break down the prejudice and misunderstanding of men's sexual health, improve the public's health literacy, and provide more health support and psychological care for men. Only in this way can we truly improve the physical and mental health of men and build a more harmonious and healthy society.